View clinical trials related to Healthy.
Filter by:As in many other countries in the world, the population in Switzerland is growing older. This also means an expansion of costs in the health system. Therefore, the investigators need to find concepts of health promotion to prevent people from getting ill and dependent of the health care system. Our project aims at developing a health promotion program for persons over 50 years of age in a rural area of Switzerland. The program's name is "bliib gsund". This occupational-therapy directed health promotion program is conducted over a period of six months in two groups of eight persons each. The aim of the program is to enhance the quality of life of the participants, to mediate the competence of integrating health-promoting aspects in their daily life, and to maintain their independence in their life as long as possible. Persons over 50 often find themselves in a phase of transition in life, such as starting retirement, the loss of family members or children moving out. This program will provide them with the ability to continue their lifestyle in a more active way. It embraces topics such as more active pursuits of interests and carrying out personally meaningful activities. In preparation of the program, the investigators conducted a needs analysis to identify the needs relating to health-promoting offers of the inhabitants living in the specified region. The results showed a high interest and need for such programs. They also helped us to identify several relevant issues to be included in the presented health-promotion program: physical exercise in daily life, healthy nutrition, getting acquainted with new technologies, fall-prevention training and maintaining social contacts. The researchers and the designated occupational therapist, who will be the moderator of the program, can develop the program based on these results. The evaluation of the program should identify the effect of the program concerning the promotion of self-efficacy, the sense of coherence, quality of life and the program objectives. A questionnaire will be distributed before the program, immediately after and six months after the program.
In this study we will explore the combined effect of Brimonidine and Timolol 0.5% (Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and a miotic effect on the pupil, however the combined effect of alpha agonist and beta blocker has not been studied.
This study involves the use of an experimental device which will measure how much propofol is present in your exhaled breath during surgery compared to how much is in your blood. The study results will look at whether the device is as accurate as conventional methods for measuring propofol levels during surgery.
The vibration stimulation is regarded as a new method of training and therapy to change afferent parts and cortical projections, which are important for motor control. This study aims to check effects of different frequency parameters for electrical cortical potentials and electrical muscular potentials in healthy young adults. 80 volunteers will participate in the study, and they will be randomly subdivided in four groups for trials. The methodology consists of electroencephalographic and electromyographic assessment before and after 15-minute vibration application with a digital vibratory pad.
Pain relief after cesarean delivery can be provided in a few ways. Most commonly, certain medications called opioids, such as morphine, are given through the vein or into the muscle. However, a more effective way to give pain relief with fewer side effects (such as nausea and slowing your breathing) is to give opioids in the spinal space as part of the medications given for a cesarean delivery. For many years, the opioid of choice was morphine due to its long anesthetic effect and acceptable side effect profile. A nation-wide disruption in the supply of preservative-free morphine has made it necessary to look for alternatives. Many institutions worldwide have used another opioid, called hydromorphone, in the spinal space for over a decade. This drug has a very good safety and side effect profile and has been used at our institution for more than a year. Of interest, while a number of different doses of hydromorphone have been used, there have been very few studies to evaluate the best dose for providing good pain relief with minimal side effects. The goal of this study is to find the best dose of spinal hydromorphone for women undergoing cesarean delivery.
The study hypothesizes that an assumed cardiovascular performance reserve is physiologically detectable. High reserve at rest characterizes a healthy person while low reserve at rest characterizes low functional capacity e.g. heart failure. The lower the reserve the severer the morbidity. The reserve may be estimated through CVRI (cardiovascular reserve index) which is computed by an algorithm composed of physiological measurements taken during the patient visit. In this study the investigators evaluate CVRI capability in prediction of functional capacity in comparison with the clinical evaluation during the same visit.
Vitamin B12and n-3 polyunsaturated fatty acids (PUFA) decrease blood homocysteine (Hcy) concentration. However, the combined effect of these nutrients on Hcy and ferritin, and C-reactive protein is limited and inconclusive. The objective was to examine the synergistic effect of vitamin B12 in combination of n-3 PUFA on plasma Hcy, ferritin, and other biochemical markers. In a randomized controlled trial, thirty eligible subjects were randomly divided into three groups, and assigned to receive 1000 μg of vitamin B12, 2g fish oil, or 1000 μg vitamin B12 and 2g fish oil respectively for 8 weeks. Plasma phospholipid (PL) fatty acids and biochemical markers were determined. we hypothesize that combination of vitamin B12 and fish oil have synergistic effect on lowering plasma concentrations of Hcy and ferritin.
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of multiple intravenous dose. The objective of this randomized, parallel, clinical trial is to evaluate the pharmacokinetic and pharmacodynamic profile of the test drug Eritromax® marketed by Blau Farmacêutica, compared to the comparator drug Eprex®, produced by Janssen-Cilag, by assessing plasma concentration of the drug and the reticulocyte count following a multiple intravenous administration during 4 weeks of 100 IU/kg in healthy subjects.
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of single intravenous dose. The objective of this randomized, crossover, clinical trial is to evaluate the pharmacokinetic and pharmacodynamic profile of the drug Eritromax® marketed by Blau Farmacêutica, compared to the product Eprex ®, produced by Janssen-Cilag, by assessing plasma concentration of the drug and the reticulocyte count following a single-dose intravenous administration of 100 IU/kg in healthy subjects.
The objective of this clinical, randomized, crossover, is to assess the pharmacodynamic profile of the drug Heparin Sodium from swine (intravenously), manufactured and marketed by Laboratory Blau Farmacêutica S/A, compared to the product of Heparin Sodium ® company APP Pharmaceuticals, through the determination of activity of the following markers: - Anti-FXa; - Anti-FIIA.